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ABSTRACT
Introduction: The diagnosis and management of
hypertension depends on accurate measurement of
blood pressure (BP) in order to target
antihypertensive treatment appropriately. Most BP
measurements take place in a clinic setting, but it has
long been recognised that readings taken out-of-
office (via home or ambulatory monitoring) estimate
true underlying BP more accurately. Recent studies
have shown that the change in clinic BP over multiple
readings is a significant predictor of the difference
between clinic and out-of-office BP. Used in
combination with patient characteristics, this change
has been shown to accurately predict a patient’s out-
of-office BP level. The present study proposes to
collect real-life BP data to prospectively validate this
new prediction tool in routine clinical practice.
Methods and analysis: A prospective, multicentre
observational cohort design will be used, recruiting
patients from primary and secondary care. All
patients attending participating centres for
ambulatory BP monitoring will be eligible to
participate. Anonymised clinical data will be collected
from all eligible patients, who will be invited to give
informed consent to permit identifiable data to be
collected for data linkage to external outcome
registries. Descriptive statistics will be used to
calculate the sensitivity, specificity, positive and
negative predictive values of the out-of-office BP
prediction tool. Area under the receiver operator
characteristic curve statistics will be used to examine
model performance.
Ethics and dissemination: Ethical approval for
this study has been obtained from the National
Research. Ethics Service Committee South Central—
Oxford A (reference; 15/SC/0184), and site-specific
R&D approval has been acquired from the relevant
NHS trusts. All findings will be presented at relevant
conferences and published in peer-reviewed journals,
on the study website and disseminated in lay and
social media where appropriate.
INTRODUCTION
High blood pressure (BP) (hypertension) is
an important risk factor for cardiovascular
disease,1 a signiﬁcant cause of morbidity and
mortality worldwide. The diagnosis and man-
agement of hypertension depends on accur-
ate measurement of BP in order to target
antihypertensive treatment at those with the
most to gain.2 The majority of BP measure-
ments take place in a clinic setting; however,
it has long been recognised that readings
taken over a 24-hour period estimate true
underlying BP more accurately because mul-
tiple readings can be averaged and it corre-
lates better with a range of cardiovascular
outcomes compared with clinic BP.3–5
Indeed, clinic BP often misclassiﬁes this true
underlying BP which can lead to incorrect
diagnosis and management.6 7
Strengths and limitations of this study
▪ This study will be the first prospective register of
patients undergoing routine clinic and ambula-
tory blood pressure (BP) monitoring in a UK
setting.
▪ It will be powered to examine the accuracy of a
new out-of-office BP prediction tool in routine
clinic practice.
▪ Despite the broad inclusion criteria for patients
in the study, the registry is unlikely to capture
many patients with normal clinic BP readings,
since these patients are not routinely referred for
ambulatory BP monitoring in routine clinical
practice.
▪ The registry is therefore unlikely to capture many
patients with masked hypertension, although it
will capture those displaying a large masked
effect.
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Depending on the direction of the error, such devia-
tions are deﬁned as a ‘white coat’ or ‘masked’ effect
(ﬁgure 1).8 9 Patients with a signiﬁcant white coat effect
have high clinic BP and a lower daytime or 24-hour
ambulatory BP and are at risk of overtreatment.8
Conversely, patients with a signiﬁcant masked effect have
high BPs with daytime or 24-hour ambulatory monitoring
but lower corresponding clinic BPs. These patients are
often underdiagnosed and potentially undertreated,9
thereby leading to increased risk of target organ
damage10 and cardiovascular mortality.11 12 White coat
and masked hypertension are terms used to describe
occasions where patients displaying such deviations have
clinic and ambulatory BP readings on opposite sides of
the diagnostic threshold for hypertension (ﬁgure 1).
In the UK, the National Institute for Health and
Clinical Excellence (NICE) now recommend out-of-ofﬁce
measurement (ambulatory or home monitoring) if BP is
raised in the clinic to conﬁrm a diagnosis of hyperten-
sion.13 While this method of diagnosis is considered cost-
effective due to a reduction in misdiagnosis caused by
white coat hypertension,2 it still results in patients with
true underlying hypertension identiﬁed by clinic BP read-
ings being sent for arguably unnecessary out-of-ofﬁce
monitoring and will not capture those patients with
masked hypertension.
Work by some of the authors14 has shown that the
change in clinic BP over multiple readings is a signiﬁ-
cant predictor of the home-clinic BP difference: a
decrease in clinic BP across multiple readings is asso-
ciated with lower BP at home and vice versa. We have sub-
sequently conﬁrmed this effect using data from previous
trials15–18 and shown that, in combination with patient
characteristics, this change can be used to accurately
predict a patient’s out-of-ofﬁce BP level.19 Used as a
triaging tool for ambulatory BP monitoring, the
PROOF-BP prediction tool19 permits detection of those
patients with a possible white coat or masked effect on
the basis of data available in a routine primary care
clinic. The tool could also be used to rule out the white
coat effect in resistant hypertensives and assist in the
monitoring of BP target attainment following treatment
titration which might be more relevant for secondary
care populations.
It is well known that BP measurements made under
controlled conditions in a research setting are not neces-
sarily comparable to those made by a physician in
routine clinical practice.20–22 Differences can occur from
the use of inadequate or uncalibrated devices,23–25 sub-
optimal measurement techniques26–28 or rounding bias
(such as terminal digit preference).29 30 Thus, a predic-
tion model shown to be accurate in a research setting is
not guaranteed to be as precise in routine clinical prac-
tice. The present study proposes to collect sufﬁcient
data from routine practice to prospectively validate the
PROOF-BP prediction tool and better understand the
relationship between BPs measured in different settings
and how they are related to cardiovascular disease risk.
This will be achieved by setting up a prospective regis-
ter of patients attending routine clinical practice for
ofﬁce and ambulatory BP monitoring. The register will
comprise of patient characteristics and clinical data and
be complementary to existing BP monitoring regis-
tries,31 32 many of which are based in specialist hyperten-
sion clinics around the world, but unique in its
consideration of multiple clinic BP readings taken in
variety of healthcare settings. Indeed, although such
data are routinely collected in clinical practice, there are
no current databases which capture this information for
research purposes. Even linked anonymised databases
such as the Clinical Practice Research Datalink (CPRD)
do not collect all the information that will be captured
within this database since multiple individual clinic and
ambulatory BP readings (from a single visit or monitor-
ing period) are rarely captured on general practice or
hospital computer systems.
METHODS
Study design
This study will use a prospective, multicentre observa-
tional cohort design, recruiting patients from primary
care and secondary care and pharmacies where possible.
The study will run from 1 May 2015 until 31 December
2017, or until a sufﬁcient number of patients have been
enrolled to enable the planned statistical analyses to be
undertaken. Subsequent follow-up of patient admissions
to hospital and mortality will continue after this date.
Study participants and setting
This study will include consecutive patients attending
participating centres in primary or secondary care (or
pharmacies) for routine BP screening. This will include
patients identiﬁed with raised BP during routine checks
in primary care, those referred to Secondary Care with
suspected hypertension, newly treated hypertension,
resistant hypertension, secondary hypertension or other
specialist conditions and those referred (by their
general practitioner) to local pharmacies for ambulatory
BP monitoring. Eligible patients will be invited to give
informed consent to allow identiﬁable data to be col-
lected for data linkage to external registries: the Ofﬁce
for National Statistics (ONS) mortality and Hospital
Episodes Statistics (HES) databases via NHS Digital’s
Data Linkage and Extract Service. The register will be
web-based to permit access from a variety of healthcare
settings.
Inclusion criteria
This study will use broad inclusion criteria to capture all
patients attending clinical practice for routine ambula-
tory BP monitoring:
▸ male and female participants,
▸ age 18 years or above,
▸ attending clinical practice for routine ambulatory BP
monitoring.
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Exclusion criteria
Participants may not enter the study if any of the follow-
ing apply:
▸ aged under 18 years old,
▸ lack of availability of basic clinical information,
▸ multiple clinic BP readings (obtained on at least
three occasions within the same visit) not recorded,
▸ ambulatory BP monitor not worn as instructed (ie,
invalid measurements taken).
Recruitment and informed consent
Practices and pharmacies will be approached via the local
NIHR Clinical Research Network, hospital sites will be
contacted by the research team directly. Sites which are
certiﬁed as having undergone training in Good Clinical
Practice (GCP) will be targeted in the ﬁrst instance.
Patients attending each study site will be screened oppor-
tunistically, that is, potential patient records will not be
screened prior to invitation to participate, but rather
those attending routine clinical practice for ambulatory
BP monitoring will be approached by a member of the
clinical care team and invited to give informed consent.
Anonymised clinical data will be collected for all patients
approached and identiﬁable patient data will be collected
in those giving informed consent (ﬁgure 2).
The participant information sheet and informed
consent form will be presented to potential participants
by the consulting healthcare team. The study participant
will personally sign and date the latest approved version
of the informed consent form before any study-speciﬁc
identiﬁable data collection is carried out. The
participant will be allowed as much time as they wish to
consider the information, and the opportunity to ques-
tion the investigator, their general practitioner or other
independent parties to decide whether they will partici-
pate in the study. The process of taking informed
consent will use the methods established in the
DESCARTE and Cough Complications Cohort (3C)
studies.33 34 That is, eligible patients will be able to
provide informed consent in one of three ways:
1. During clinic attendance, patients will be ask by par-
ticipating staff if they would be willing to consider
giving consent for identiﬁable data to be collected
for data linkage purposes. Patients will be given an
information sheet and consent form and if willing to
do so, complete it during the same clinic.
2. Those wishing more time to consider participation
will be asked to take the information home and, if
willing to participate, return a completed consent
form during their next visit when they return the
ambulatory BP monitor.
3. Those forgetting to provide consent at either visit
may return a signed consent form to the participat-
ing centre by post.
All investigators taking informed consent at participat-
ing centres will be expected to have undergone training
in GCP. Where this is not the case, training will be
offered via the NIHR Clinical Research Network. Each
participant will retain a copy of the signed informed
consent form and the original will be retained at the
study site. A copy of the signed form will be scanned
and uploaded onto the study database.
Figure 1 Definitions of
normotension, hypertension and
the home-clinic blood pressure
(BP) difference. BP, blood
pressure; out-of-office BP may be
defined by home or daytime
ambulatory BP measurements.
Individuals with a white coat
effect (negative home-clinic
difference) may be normotensive,
hypertensive or white coat
hypertensive. Those with a
masked effect (positive
home-clinic difference) may be
normotensive, hypertensive or
masked hypertensive. Those with
an out-of-office >135/85 mm Hg
(hypertension) may be masked or
sustained hypertensives.
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Figure 2 Patient recruitment and data collection.
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Anonymised data collection
Anonymised clinical data from all patients eligible for
the study will be collected and entered onto the study
database by participating staff at each data collection
site. Individual patient consent is not required for anon-
ymised data collection and will not be sought, as is
common in routine clinical audits and anonymised
observational cohort studies,35 36 although those wishing
to opt out will be able to if they wish. All sites will be
offered an automated BP monitoring device (Omron
M10-IT or equivalent) to assist with the collection of
multiple clinic BP readings, but can choose to continue
using their standard monitor, so long as at least three
readings are taken and recorded. The Omron M10-IT
device automatically takes three clinic readings at 30 s to
1 min intervals and calculates an average. The individual
readings and the averaged BP can be viewed on the
monitor after measurement. Current guidelines in the
UK13 and abroad21 37 recommend that 2–3 clinic read-
ings are taken when screening for hypertension and
thus collection of data for the minimum data set
required in the present study will not constitute a devi-
ation from usual care (although documentation of these
individual readings may incur additional time for which
participating centres will be reimbursed, where appro-
priate). Instructions will be provided for clinic and
ambulatory BP monitoring (based on clinical guide-
lines),13 but no formal procedure will be put in place
for checking if measurement protocols have been
adhered to; such ﬂexibility will be allowed to reﬂect true
clinical practice. Clinic readings taken at the time of
referral for ambulatory BP monitoring or at monitor
ﬁtting will be deemed acceptable for inclusion in the
study, but no limit on the period of time between the
two will be speciﬁed. Where available, data from
repeated clinic/ambulatory measurements in the same
patient will be collected and used to assess the sensitivity
of the tool used with repeated measurements.
A minimum data set will be required for all eligible
patients and include patient characteristics and clinical
data related to BP measurements and cardiovascular
disease risk (table 1). Where data are routinely collected
and available, additional information relating to speciﬁc
cardiovascular risk factors will be collected to permit
subgroup analyses by risk group (table 1).
Identifiable data collection
Eligible patients will be invited to give informed consent
to allow identiﬁable data to be collected for data linkage
to external registries. The prespeciﬁed identiﬁable data
to be collected are detailed in table 1. These data will be
used to link clinical data collected at baseline to
Table 1 Identifiable and anonymised data variables
Anonymised clinical data
Identifiable patient data Minimum data set Additional variables (if available)*
Patient name Age Waist circumference
Date of birth Sex Alcohol consumption
Current address Ethnicity Right and left arm clinic blood pressure
Post code Smoking status History of left ventricular hypertrophy
NHS number Height Sodium
Weight Potassium
3–6 clinic blood pressure readings Calcium
Daytime ABP Total cholesterol
Night-time ABP HDL cholesterol
24 ABP Triglycerides
Number of readings HbA1c
Reason for monitoring Plasma renin levels
Diagnosis of hypertension Creatinine
History of hypertension eGFR
History of myocardial infarction Albumin:creatinine ratio
History of stroke Urinalysis
History of heart failure Thyroid-stimulating hormone
History of diabetes Free Thyroxine (T4)
History of chronic kidney disease Albumin
History of atrial fibrillation Alanine transaminase (ALT)
Antihypertensive prescription Aspartate aminotransferase (AST)
Statin prescription Alkaline phosphatase (ALP)
Antiplatelet prescription Total bilirubin
γ-Glutamyltransferase
*Blood analyses are only routinely conducted in Secondary Care. Only measurements taken during the baseline visit will be deemed
acceptable for inclusion.
ABP, ambulatory blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein;
NHS, National Health Service.
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outcome data via the NHS Digital’s Data Linkage and
Extract Service. This service tracks patient events via the
Hospital Episode Statistics and the Ofﬁce for National
Statistics death register, using NHS numbers and other
identiﬁable information and will allow ascertainment of
all hospital admissions and/or death status following
enrolment into the study.
Study database
Each data collection site will store their data locally
using standard clinical systems and upload a copy of
these data to a secure central database at the study
coordinating centre (University of Oxford). Local staff
will be trained to upload data and automated checks will
be used to ensure data entry errors are kept to a
minimum. Data will be entered into two separate study
databases, one for anonymised data and one for identiﬁ-
able data. A unique study identiﬁer will automatically be
generated for every patient entered onto the anon-
ymised study database and this will be entered onto the
database of patient identiﬁers for those patients giving
informed consent (permitting linkage of identiﬁable
and anonymised data). Double data entry will be
employed for entry of the unique study identiﬁer onto
the database of patient identiﬁers to ensure accuracy.
Both study databases will include secure login for staff at
participating sites and facilities for manual data entry,
upload of ambulatory BP monitoring data and consent
forms (contained in .csv and .pdf ﬁles).
Data protection and storage
Identiﬁable data will be stored at each data collection site
in accordance with data protection guidelines and NHS
policy, and on the secure study database hosted by the
coordinating institution. Data access will be limited to
speciﬁc members of the research team (trained in data
protection policy), including the principle investigator
(as study guarantor), data manager and database pro-
grammer. All data used in analyses and published
outputs will be anonymised. Applications for data sharing
with researchers from other research organisations will
be reviewed by the registry steering committee and deci-
sions on access will be subject to satisfactory review of a
study protocol. All data and study documentation will be
stored for subsequent scientiﬁc validation and audit as
required. Data will be archived following completion of
the study in line with GCP guidelines and documents will
be retained for a minimum of 5 years after publication in
line with the University Code of Practice for Research.
STATISTICAL ANALYSIS
Outcomes
The primary outcome of this study will be to deﬁne the
accuracy of the PROOF-BP prediction tool19 in terms of
the proportion of true-positive, true-negative, false-
positive and false-negative results in a typical population
attending routine clinical practice with suspected or
diagnosed hypertension. Secondary outcomes will be
examined where sufﬁcient data are available and
include assessment of model performance in different
subgroups—age (young vs old), cardiovascular disease
risk (high vs low risk according to previous history and
risk scores using data where available), those with
chronic kidney disease, diabetes and across healthcare
settings: primary care, secondary care and pharmacy
settings.
In the longer term, linked data from the registry will
be used to examine how BP data collected at baseline
predict long-term clinical outcomes (eg, hospital admis-
sion with myocardial infarction/stroke and mortality). It
is anticipated that the registry will become a useful
source of data permitting further investigations into BP
monitoring by a variety of means and cardiovascular
disease risk factor data linked to cardiovascular disease
morbidity and mortality in routine clinical practice.
Data analysis
A detailed analysis plan will be agreed to by the study
steering committee prior conducting any analyses.
Brieﬂy, data collected from the registry will be used to
prospectively validate the PROOF-BP prediction tool.
Descriptive statistics will be used to deﬁne the number
of patients classed as true positives (sustained hyperten-
sives), false positives (white coat hypertensives), true
negatives (normotensives) and false negatives (masked
hypertensives) (ﬁgure 1). These will be used to calculate
the sensitivity, speciﬁcity, positive predictive value and
negative predictive value of the PROOF-BP prediction
tool. Area under the receiver operator characteristic
(AUROC) curve statistics will be used to examine the
prediction model performance.
χ2 statistics will be used to compare the classiﬁcation
of patients’ hypertensive status according to the predic-
tion model and existing strategies13 37 for the diagnosis
and management of hypertension. An improvement in
patient classiﬁcation of >10% or reduction in the usage
of out-of-ofﬁce monitoring of >20% will be deemed as
successful validation. These thresholds were chosen
because they were deemed to represent a clinically sig-
niﬁcant improvement in diagnostic accuracy which
might be expected to change clinical practice. Where
model validation is found to be unsuccessful, recalibra-
tion will be explored.
Other secondary outcomes will be examined with χ2
statistics comparing the classiﬁcation of patients’ hyper-
tensive status across subgroups (by setting, age group,
sex, cardiovascular disease risk status, comorbid condi-
tions and treatment status). Sensitivity analyses will exam
the accuracy of the PROOF-BP prediction tool using
24 hour BP to deﬁne the home-clinic BP difference,
where it is collected. Linked data will be used to
examine the association between the ‘adjusted clinic
blood pressure’ (estimated from the PROOF-BP predic-
tion model) and clinical outcomes (all-cause mortality,
cardiovascular mortality, hospital admission with
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myocardial infarction or stroke) using the Cox propor-
tional hazards models.
Sample size
Based on the initial validation phase of the PROOF-BP
prediction model, conducted using data from previous
studies,19 accrual of data from up to 1000 patients would
allow for estimation of hypertensive status with an accur-
acy of ±1–3%. This assumes 71% of patients will be
classed as true positives, 24% as true negatives, 3% as
false positives and 2% as false negatives. In a population
of 1000 patients, it would be possible to estimate these
rates with the following 95% CIs: true positive 71%
(68% to 74%), true negative 24% (21% to 27%), false
positive 3% (2% to 4%) and false negative 2% (1% to
3%) (table 2). If these point estimates were to differ, or
indeed a slightly lower number of patients were
enrolled, the impact on the accuracy of the study results
would be minimal (table 2). The sample size of up to
1000 patients has been speciﬁed to ensure that the pre-
speciﬁed subgroup analysis can be undertaken and be
adequately powered.
Approximately 182 patients would be required in each
subgroup to examine the secondary outcomes proposed
in the proposed study. This is based on a likelihood ratio
test of two proportions detecting a 10% difference in the
classiﬁcation of hypertensive status between two sub-
group populations (primary care vs secondary care,
primary care vs pharmacies, older vs younger patients,
high-risk vs low-risk patients) with a signiﬁcance level
of 0.05 and 90% power. Assuming correct classiﬁcation
of 95% of patients in one group and 85% in the other,
∼364 patients (182 in each group) would be required
to demonstrate this signiﬁcant difference. Thus, our
recruitment target of 1000 patients should be sufﬁ-
cient to answer primary and secondary outcomes, pro-
vided recruitment is appropriately distributed across
clinic settings and patient characteristic subgroups.
Recruitment of the sample size above should be
achievable with recruitment of up to 10 primary care/
pharmacy sites (each recruiting up to 50 patients) and
one secondary care site (recruiting up to 500 patients).
With patient attendance for routine BP monitoring at
individual sites likely to be signiﬁcantly higher, these
targets are eminently achievable.
ETHICS AND DISSEMINATION
Ethical approval for this study has been obtained from
the National Research Ethics Service Committee South
Central—Oxford A (reference; 15/SC/0184), and site-
speciﬁc R&D approval has been acquired from the rele-
vant NHS trusts.
All ﬁndings will be presented at relevant conferences
and published in peer-reviewed journals, on the study
website and disseminated in lay and social media where
appropriate. The investigators will be involved in review-
ing drafts of the manuscripts, abstracts, press releases
and any other publications arising from the study. The
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authors will acknowledge that the study was funded by
the Medical Research Council. Authorship will be deter-
mined in accordance with the ICMJE guidelines and
other contributors will be acknowledged.
Relevant results will be made available for the next
iterations of the NICE Hypertension guidelines and
other relevant national guidelines. It is anticipated that
these will support better patient-centred management
plans for the diagnosis and management of hyperten-
sion and cardiovascular disease risk.
DISCUSSION
This protocol describes the ﬁrst prospective register of
patients undergoing routine clinic and ambulatory BP
monitoring in a UK setting. This is important, since the
UK is leading the way in the promotion of ambulatory
BP monitoring for the diagnosis and management of
hypertension.13 Thus, the proposed register is likely to
contain a broader range of patients attending routine
practice than other registries based in specialist hyper-
tension clinics around the world,31 32 and unique in its
consideration of multiple clinic BP readings taken in
variety of healthcare settings.
Despite the broad inclusion criteria for patients to be
included in the study, it is unlikely to capture many
patients with normal clinic BP readings, since these
patients are not routinely referred for ambulatory BP
monitoring in routine clinical practice. Thus, the registry
is unlikely to capture many patients with masked hyper-
tension (although it will capture those displaying a large
masked effect) and further work will be required to valid-
ate the PROOF-BP prediction tool19 in routine practice
in this particular population. The register will however
permit the prospective validation of this tool using data
from real-life clinical settings, and allow the accuracy of
existing BP monitoring strategies to be examined in
routine clinical practice. It is hoped that this work will
improve the diagnosis and management of hypertension
in primary and secondary care, allowing better targeting
of treatment at those patients with the most to gain.
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